Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

12.04.2019 | leitlinien für die praxis

Insulintherapie bei Typ 2 Diabetes mellitus (Update 2019)

verfasst von: Monika Lechleitner, Martin Clodi, Heidemarie Abrahamian, Helmut Brath, Johanna Brix, Heinz Drexel, Peter Fasching, Bernhard Föger, Claudia Francesconi, Elke Fröhlich-Reiterer, Jürgen Harreiter, Sabine E. Hofer, Friedrich Hoppichler, Joakim Huber, Susanne Kaser, Alexandra Kautzky-Willer, Bernhard Ludvik, Anton Luger, Julia K. Mader, Bernhard Paulweber, Thomas Pieber, Rudolf Prager, Birgit Rami-Merhar, Michael Resl, Michaela Riedl, Michael Roden, Christoph H. Saely, Christian Schelkshorn, Guntram Schernthaner, Harald Sourij, Lars Stechemesser, Harald Stingl, Hermann Toplak, Thomas C. Wascher, Raimund Weitgasser, Yvonne Winhofer-Stöckl, Sandra Zlamal-Fortunat

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Leitlinie nimmt Bezug auf die Indikation und praktische Umsetzung der Insulintherapie bei Typ 2 Diabetes, insbesondere auch im Hinblick auf die unterschiedlichen Formen der Insulintherapie.
Vorheriger Artikel Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)
Nächster Artikel Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen (Update 2019)
Literatur
1.
American Diabetes Association. Approaches to glycemic treatment: standard of medical care in diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S73–S85.CrossRef
2.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJJB, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461–98CrossRef
3.
UK Prospective Diabetes Study (UKPDS Group). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–52.CrossRef
4.
Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRef
5.
Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, Reda DJ, Emanuele NV, VADT Study Group.. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veteran Affairs Diabetes Trail (VADT). Diabetologia. 2018;61:295–9.CrossRef
6.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
7.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef
8.
Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61:58–65.CrossRef
9.
American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S55–S64.CrossRef
10.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42.CrossRef
11.
Ismail-Beigi F, Moghissi E, Tikin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.CrossRef
12.
Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogues. Drug Healthc Patient Saf. 2010;2:213–23.PubMedPubMedCentral
13.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.CrossRef
14.
Woo VC. A review of the clinical efficacy and safety of insulin deglutec and glargine 300 U/mL in the treatment of diabetes mellitus. Clin Ther. 2017;39:S12–S33.CrossRef
15.
Blair HA, Keating GM. Insulin Glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–74.CrossRef
16.
Robinson JD, Neumiller JJ, Campbell RK. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec? Drugs. 2012;72:2319–25.CrossRef
17.
Lamos EM, Younk LM, Davis STN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.PubMedPubMedCentral
18.
Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1 years patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20:541–8.CrossRef
19.
Rodacki M, Carvalho RM, Zajdenverg L. The potential effect of ultra-long insulin degludec on glycaemic variability. Diabetes Res Clin Pract. 2017;133:92–103.CrossRef
20.
Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1,2 and 3 studies: glycemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–67.CrossRef
21.
Heller S, Buse J, Fisher M, et al. Insulin deglutec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97.CrossRef
22.
Garber AJ, King AB, Del Prato St, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase3, randomised, open label, treat-to target non inferiority trial. Lancet. 2012;379:1498–507.CrossRef
23.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB, DEVOTE Study Group.. Efficacy and safety of Degludec versus Glargine in type 2 diabetes. N Engl J Med. 2017;377:723–32.CrossRef
24.
Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:48–57.CrossRef
25.
Herman WH, Buse JB, Arakaki RF, Dungan KM, Jiang HH, Jacobson JG, Fahrbach JL. Concomitant oral antihyperglycemic agent use and associated outcomes after initiation of insulin therapy. Endocr Pract. 2011;17:563–7.CrossRef
26.
Donner T, Munoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab. 2012;97:1405–13.CrossRef
27.
Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012;344:e1771.CrossRef
28.
Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311:2288–96.CrossRef
29.
Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study Group.. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–36.CrossRef
30.
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, EMPA-REG BASALTM trial investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–48.CrossRef
31.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcome and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.CrossRef
32.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.CrossRef
33.
Gautier JF, Monguillon P, Verier-Mine O, Valensi P, Fiquet B, Dejager S, Charbonnel B. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin? A randomized controlled trial of DPP-4 inhibitors versus insulin secretagogues. Diabetes Res Clin Pract. 2016;116:26–32.CrossRef
34.
Rhinehart AS. Adding GLP-1 receptor agonist therapy to basal insulin for postprandial glucose control. Clin Diabetes. 2015;33:73–5.CrossRef
35.
Digenio A, Karve S, Candrilli SD, Dalal M. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med. 2014;126:49–59.CrossRef
36.
LEADER Trial Investigators, Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcome in type 2 diabetes. N Engl J Med. 2016;375:311–22.CrossRef
37.
Downie M, Kilou G, Wong J. Initiantion and intensification strategies in type 2 diabetes management: a comparison of basal plus and premix regimens. Diabetes Ther. 2016;7:641–57.CrossRef
38.
Meece J. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9:877–90CrossRef
39.
Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensity Premix I Investigators. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37:2084–90.CrossRef
40.
Siegmund T, Pfohl M, Forst T, et al. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment—a prospective observational study in 2202 patients. Diabetes Metab Syndr. 2017;11:51–7.CrossRef
41.
Pfeiffer KM, Basse A, Lee XY, Waldman LT. Diabetes management and healthcare resource use when intensifying from basal insulin to basal-bolus: a survey of type 2 diabetes patients. Diabetes Ther. 2018;9:1931–44.CrossRef
42.
Chlup R, Runzis S, Castaneda J, Lee SW, Nguyen X, Cohen O. Complex assessment of metabolic effectiveness of insulin pump therapy in patients with type 2 diabetes beyond HbA1c reduction. Diabetes Technol Ther. 2018;20:153–9.CrossRef
Metadaten
Titel
Insulintherapie bei Typ 2 Diabetes mellitus (Update 2019)
verfasst von
Monika Lechleitner
Martin Clodi
Heidemarie Abrahamian
Helmut Brath
Johanna Brix
Heinz Drexel
Peter Fasching
Bernhard Föger
Claudia Francesconi
Elke Fröhlich-Reiterer
Jürgen Harreiter
Sabine E. Hofer
Friedrich Hoppichler
Joakim Huber
Susanne Kaser
Alexandra Kautzky-Willer
Bernhard Ludvik
Anton Luger
Julia K. Mader
Bernhard Paulweber
Thomas Pieber
Rudolf Prager
Birgit Rami-Merhar
Michael Resl
Michaela Riedl
Michael Roden
Christoph H. Saely
Christian Schelkshorn
Guntram Schernthaner
Harald Sourij
Lars Stechemesser
Harald Stingl
Hermann Toplak
Thomas C. Wascher
Raimund Weitgasser
Yvonne Winhofer-Stöckl
Sandra Zlamal-Fortunat
Publikationsdatum
12.04.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-1492-7

Weitere Artikel der Sonderheft 1/2019

Diabetesmanagement im Krankenhaus (Update 2019)

  • Open Access
  • leitlinien für die praxis

Rauchen, Alkohol und Diabetes mellitus (Update 2019)

  • leitlinien für die praxis

Geriatrische Aspekte bei Diabetes mellitus (Update 2019)

  • leitlinien für die praxis

Diabetesschulung und -beratung bei Erwachsenen mit Diabetes (Update 2019)

  • leitlinien für die praxis

Ernährungsempfehlungen bei Diabetes mellitus (Update 2019)

  • Open Access
  • leitlinien für die praxis

Diagnose und Management der Osteoporose bei Diabetes mellitus (Update 2019)

  • Open Access
  • leitlinien für die praxis